scholarly journals Letter: programmed cell death protein-1-targeted immunotherapy for advanced hepatocellular carcinoma-authors' reply

2019 ◽  
Vol 50 (3) ◽  
pp. 341-342
Author(s):  
Bernhard Scheiner ◽  
Matthias Pinter
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Advanced Hepatocellular Carcinoma ◽  
Cell Death Protein ◽  
Targeted Immunotherapy

scholarly journals Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort

2019 ◽  
Vol 49 (10) ◽  
pp. 1323-1333 ◽  
Author(s):  
Bernhard Scheiner ◽  
Martha M. Kirstein ◽  
Florian Hucke ◽  
Fabian Finkelmeier ◽  
Kornelius Schulze ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Real World ◽  
Safety Data ◽  
Advanced Hepatocellular Carcinoma ◽  
Efficacy And Safety ◽  
Cell Death Protein ◽  
Targeted Immunotherapy

Abstract 417: Role of programmed cell death protein-1 (PD-1)-targeted immunotherapy in hepatocellular carcinoma

2021 ◽  
Author(s):  
Shaohua Li ◽  
Jie Mei ◽  
Qiaoxuan Wang ◽  
Wei Wei ◽  
Lianghe Lu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Cell Death Protein ◽  
Targeted Immunotherapy

scholarly journals Efficacy and Safety of Anti-Programmed Cell Death Protein-1 Immunotherapy for Advanced Hepatocellular Carcinoma With Pulmonary Metastases: A Single-Center, Retrospective Study

2021 ◽  
Vol 20 ◽  
pp. 153303382110381
Author(s):  
Mei Zhao ◽  
Yiruo Zhang ◽  
Hua Wang ◽  
Pingping Liu ◽  
Jie Da ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Death ◽  
Retrospective Study ◽  
Programmed Cell Death ◽  
Disease Control ◽  
Pulmonary Metastases ◽  
Advanced Hepatocellular Carcinoma ◽  
Efficacy And Safety ◽  
Advanced Hcc ◽  
Cell Death Protein

Background: Anti-programmed cell death protein-1 immunotherapy has been approved as a new treatment option for advanced hepatocellular carcinoma (HCC) based on the promising results of several studies. Methods: This retrospective study included 71 patients with advanced HCC treated with anti-programmed cell death protein-1 immunotherapy between June 1, 2017 and September 30, 2020 at the First Affiliated Hospital of Anhui Medical University. Responses to pulmonary metastases were evaluated. Results: The median follow-up duration was 7.73 months (95% confidence interval (CI), 4.48-10.98). Of 71 patients, the overall response rate (ORR) and disease control rate (DCR) were 32% (23/71) and 73% (52/71), respectively. The median progression-free survival (PFS) and overall survival (OS) were 4.90 (95% CI, 2.71-7.09) and 20.23 (95% CI, 6.87-33.59) months, respectively. Forty-two patients had HCC pulmonary metastases, whereas 29 did not have pulmonary metastasis. No significant differences were observed in the ORR (38% [16/42] vs. 24% [7/29], P = 0.22) and DCR (74% [31/42] vs. 72% [21/29], P = 0.90) between groups. In patients with pulmonary metastases, the median disease control duration of pulmonary lesions was significantly longer than extrapulmonary lesions (Not Reached vs. 12.37 months, P = 0.048). Pulmonary metastases were not associated with an increased incidence of adverse events (67% vs. 62%, P = 0.69). Conclusions: Anti-programmed cell death protein-1 immunotherapy showed promising efficacy and safety in patients with advanced HCC, with good responses observed in pulmonary metastases. The mechanism underlying the differences in responses between pulmonary and extrapulmonary metastases requires further investigation.

scholarly journals A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China

2021 ◽  
Vol 11 ◽  
Author(s):  
Sihui Zhu ◽  
Chenxi Liu ◽  
Yanbing Dong ◽  
Jie Shao ◽  
Baorui Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Death ◽  
Liver Cancer ◽  
Programmed Cell Death ◽  
Intrahepatic Cholangiocarcinoma ◽  
Real World ◽  
Liver Tumors ◽  
Chinese Patients ◽  
First Line ◽  
Cell Death Protein

Lenvatinib has been ratified as a first-line medication for advanced liver tumors by the American Food and Drug Administration. To assess the effectiveness and security of Lenvatinib in the Chinese population in a real-world setting, we enrolled 48 patients with unresectable liver cancer, managed from December 2018 to March 2021. Among them, 9 and 39 (83.30% men) patients had intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC), respectively. Twenty-one (43.75%) patients had progressive disease after first-line treatment, and others (56.25%) had not receiving systemic treatment. Lenvatinib was administered alone or in combination with a programmed cell death protein 1 antibody (anti-PD-1). Treatment duration, median progression-free survival (mPFS), and median overall survival (mOS) were examined. The mOS and mPFS were 22.43 and 8.93 months, respectively. Of HCC patients treated with Lenvatinib only, the mOS and mPFS were 22.43 and 11.60 months, respectively. The corresponding values for HCC cases managed with anti-PD-1 combined with Lenvatinib were 21.77 and 7.10 months, respectively. ICC patients did not reach the mOS and their mPFS was 8.63 months. The present findings support the efficacy and security of Lenvatinib in the real-world therapy of Chinese patients with unresectable liver cancer.

Sign in / Sign up

Export Citation Format

Share Document